Exchange Bulletin

Endo International PLC (ENL) To Trade On Toronto Stock Exchange


March 3, 2014

Endo International PLC (the "Company") - An application has been granted for the original listing in the Industrial category of approximately 195,031,000 ordinary shares (the "Shares") of Endo International plc (the "Company"), of which approximately 151,589,000 will be issued and outstanding and approximately 43,442,000 will be reserved for issuance, upon completion of a series of transactions (collectively, the "Transaction"), including a plan of arrangement involving, among others, Paladin Labs Inc. (Symbol: PLB) ("Paladin") and Endo Health Solutions Inc. (NASDAQ Symbol: ENDP) ("Endo"), which are described in the management information circular of Paladin dated January 21, 2014 (the "Circular") (the "Transaction").

Should the closing of the Transaction occur as scheduled, the Shares will be posted for trading on Toronto Stock Exchange at the opening of business on Monday, March 3, 2014.

Transfers of Shares could be subject to Irish stamp duty (currently at the rate of 1% of the higher of the price paid or the market value of the Shares acquired). However, transfers of Shares effected by means of the transfer of book entry interests in CDS or DTC will not be subject to Irish stamp duty. Payment of Irish stamp duty is generally a legal obligation of the transferee. Please refer to the Circular for additional information regarding the Irish stamp duty.

Additional information on the Shares may be found in the Circular, which is available at www.SEDAR.com. Capitalized terms not otherwise defined herein are as defined in the Circular.

Stock Symbol: "ENL" CUSIP: G30401 10 6 Currency CDN$



Temporary Market Maker: JitneyTrade Inc.
Other Markets: The Shares will be listed on NASDAQ Global Select Market and posted for trading under the symbol "ENDP" upon completion of the Transaction.
Head Office Address: 25-28 North Wall Quay
International Financial Services Centre
Dublin 1, Ireland
Website: www.endo.com
Head Office Telephone Number: (011) 353-1-649-2000
Fax Number: (610) 884-7159
Investor Relations: Blaine Davis
Tel.: (484) 216-7158
Email: davis.blaine@endo.com


Jonathan Neely
Tel.: (484) 216-7158
Email: jonathan@endo.com
Incorporation: The Company is a public limited company incorporated in Ireland pursuant to the Companies Acts 1963 to 2013 on October 31, 2013.
Fiscal Year End: December 31
Chief Financial Officer: Suketu P. Upadhyay
Corporate Secretary: Caroline B. Manogue
Nature of Business: The Company is a holding company which, upon closing of the Transaction, will wholly own, among other companies, Paladin, a specialty pharmaceutical company focused on acquiring or in-licensing pharmaceutical products for the Canadian and world markets, and Endo, a U.S.-based, specialty healthcare company focused on branded and generic pharmaceuticals, devices and services.
Transfer Agent & Registrar: The U.S. transfer agent and registrar for the Shares is Computershare Trust Company N.A. at its principal office in Canton, Massachusetts, USA, and the Canadian co-transfer agent and registrar for the Shares is Computershare Investor Services Inc. at its principal office in Toronto, Canada.
Dividends: The Company does not expect to pay dividends for the foreseeable future.